Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) gapped up prior to trading on Monday. The stock had previously closed at $12.30, but opened at $12.72. Bayer Aktiengesellschaft shares last traded at $12.71, with a volume of 50,995 shares trading hands.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the company. Zacks Research upgraded Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Thursday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Bayer Aktiengesellschaft presently has an average rating of "Buy".
Get Our Latest Stock Report on BAYRY
Bayer Aktiengesellschaft Stock Performance
The firm has a market cap of $49.83 billion, a price-to-earnings ratio of -24.86, a price-to-earnings-growth ratio of 1.86 and a beta of 0.57. The company has a quick ratio of 0.67, a current ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a fifty day moving average price of $13.53 and a 200-day moving average price of $12.64.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.06. The business had revenue of $12.53 billion for the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, analysts expect that Bayer Aktiengesellschaft will post 1.27 earnings per share for the current fiscal year.
Bayer Aktiengesellschaft Company Profile
(
Get Free Report)
Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.
Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women's health, oncology, hematology and specialty therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bayer Aktiengesellschaft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list.
While Bayer Aktiengesellschaft currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.